We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD. Our early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel ...
expected 2026-11-05
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076650 | EDGAR | 86K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029149 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0000950170-24-023177 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0000950170-23-005582 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001564590-22-008060 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009905 | EDGAR | — |
| 2020-03-09 | 2019-12-31 | 0001564590-20-009385 | EDGAR | — |
| 2019-03-06 | 2018-12-31 | 0001564590-19-006514 | EDGAR | — |
| 2018-03-07 | 2017-12-31 | 0001564590-18-004750 | EDGAR | — |
| 2017-03-08 | 2016-12-31 | 0001564590-17-003716 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-338244 | EDGAR | — |
| 2025-11-03 | 2025-09-30 | 0001193125-25-262646 | EDGAR | 49K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106599 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069342 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125547 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094109 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-057139 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061200 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040681 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019775 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023283 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001564590-22-028780 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-338019 | EDGAR | — |
| 2026-03-13 | 0001193125-26-106144 | EDGAR | 1K words |
| 2026-03-12 | 0001193125-26-104199 | EDGAR | — |
| 2026-03-09 | 0001193125-26-097577 | EDGAR | — |
| 2026-02-27 | 0001193125-26-082520 | EDGAR | — |
| 2026-02-26 | 0001193125-26-076530 | EDGAR | — |
| 2025-12-01 | 0001193125-25-303862 | EDGAR | — |
| 2025-11-03 | 0001193125-25-262519 | EDGAR | — |
| 2025-10-16 | 0001193125-25-241546 | EDGAR | — |
| 2025-08-11 | 0000950170-25-106529 | EDGAR | — |
230 total filings indexed. 198 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001582313 |
| Ticker | XENE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | A1 |
| Website | https://www.xenon-pharma.com |
| Listed | 2014-11-05 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/XENE (~200 tokens, structured JSON with cryptographic provenance)